Journal: Cancer Medicine

Article Title: Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

doi: 10.1002/cam4.7349

Figure Lengend Snippet: Baseline characteristics of the study population.

Article Snippet: In this context, the ALTER0303 trial showed that third‐line treatment with anlotinib (a multitarget small‐molecule antiangiogenic drug) improved progression‐free survival (PFS) in NSCLC patients.

Techniques: Recombinant

Journal: Cancer Medicine

Article Title: Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

doi: 10.1002/cam4.7349

Figure Lengend Snippet: Univariable and multivariable Cox regression analyses of factors associated with progression‐free survival.

Article Snippet: In this context, the ALTER0303 trial showed that third‐line treatment with anlotinib (a multitarget small‐molecule antiangiogenic drug) improved progression‐free survival (PFS) in NSCLC patients.

Techniques:

Journal: Cancer Medicine

Article Title: Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

doi: 10.1002/cam4.7349

Figure Lengend Snippet: Univariable and multivariable Cox regression analyses of factors associated with overall survival.

Article Snippet: In this context, the ALTER0303 trial showed that third‐line treatment with anlotinib (a multitarget small‐molecule antiangiogenic drug) improved progression‐free survival (PFS) in NSCLC patients.

Techniques:

Journal: RSC Advances

Article Title: An innovative small molecule for promoting neuroreparative strategies

doi: 10.1039/c7ra11812k

Figure Lengend Snippet: Histograms and densitometric WB analysis from SW480 cells. (A) TLR-4 and P-gp expression in SW480 cells ((C) unstimulated cells; (LPS) cells stimulated with 1 μg ml −1 LPS; (MC111) cells stimulated with 250 μM MC111. (B) Activation of NF-κB performed by analysis of active phosphorylated form (p-IκB). (C) Modulation of TLR-4 expression after P-gp silencing (left) and P-gp expression after TLR-4 silencing (right), respectively (siC: P-gp or TLR-4 silenced unstimulated cells; siLPS: P-gp or TLR-4 silenced cells stimulated with 1 μg ml −1 LPS; P-gp or TLR-4 silenced cells stimulated with 250 μM MC111).

Article Snippet: In this study, a new regenerative strategy to treat several neurodegenerative diseases is suggested by the use of a multitarget approach induced by our small molecule, MC111.

Techniques: Expressing, Activation Assay

Journal: RSC Advances

Article Title: An innovative small molecule for promoting neuroreparative strategies

doi: 10.1039/c7ra11812k

Figure Lengend Snippet: Representative images of Dorsal Root Ganglia (DRG) neurons after 72 h culture. (A–F) Phase contrast microscopy of DRG neurons cultured in the presence of BMS alone (A and D), BMS + 1 μg ml −1 NGF (B and E), BMS + 1 μM MC111 (C and F). (G–L) Immunocytochemical staining for βIII tubulin (FITC) of DRG neurons cultured in the presence of BMS alone (G and J), BMS + 1 μg ml −1 NGF (H and K), BMS + 1 μM MC111 (I and L).

Article Snippet: In this study, a new regenerative strategy to treat several neurodegenerative diseases is suggested by the use of a multitarget approach induced by our small molecule, MC111.

Techniques: Microscopy, Cell Culture, Staining

Journal: RSC Advances

Article Title: An innovative small molecule for promoting neuroreparative strategies

doi: 10.1039/c7ra11812k

Figure Lengend Snippet: Quantification of DRG neurons neurite outgrowth after 72 h culture. BSM (white columns), BMS + 1 μg ml −1 NGF (grey columns), BMS + 1 μM MC111 (black columns). (A) Percentage of neuron sprouting neurites; (B) length of longest neurite; (C) neurite number per cell; (D) sum of neurite length. The values were the means ± SD from three experiments. * P < 0.05 ** P < 0.01 versus control was estimated by Student's t -test.

Article Snippet: In this study, a new regenerative strategy to treat several neurodegenerative diseases is suggested by the use of a multitarget approach induced by our small molecule, MC111.

Techniques: Control

Journal: RSC Advances

Article Title: An innovative small molecule for promoting neuroreparative strategies

doi: 10.1039/c7ra11812k

Figure Lengend Snippet: MC111 activities profile.

Article Snippet: In this study, a new regenerative strategy to treat several neurodegenerative diseases is suggested by the use of a multitarget approach induced by our small molecule, MC111.

Techniques:

Journal: Molecular Cancer

Article Title: Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

doi: 10.1186/s12943-024-02167-9

Figure Lengend Snippet: FGFR genomic alterations in lung cancer

Article Snippet: These approaches include small-molecule FGFR inhibitors that target the ATP-binding site of the tyrosine kinase domain of various growth factor receptors (multitarget TKIs), selective TKIs that specifically target the kinase domain of FGFRs, and biological agents (Fig. ).

Techniques: Mutagenesis

Journal: Molecular Cancer

Article Title: Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

doi: 10.1186/s12943-024-02167-9

Figure Lengend Snippet: Targeting FGF/FGFR signaling in lung cancer. Drugs targeting FGFR that are at the clinical stage include multitarget TKIs (nintedanib, dovitinib, pazopanib, and ponatinib) and selective TKIs (pan-FGFR inhibitors such as erdafitinib and rogaratinib; FGFR1/2/3 inhibitors such as pemigatinib, infigratinib and fexagratinib). FP-1039, which targets FGF, has also been investigated in clinical trials. New strategies for targeting FGF/FGFR include the use of FGFR degraders (DGY-09-192 and LC-MB12), specific FGFR inhibitors and anti-FGF2 aptamers

Article Snippet: These approaches include small-molecule FGFR inhibitors that target the ATP-binding site of the tyrosine kinase domain of various growth factor receptors (multitarget TKIs), selective TKIs that specifically target the kinase domain of FGFRs, and biological agents (Fig. ).

Techniques: Clinical Proteomics

Journal: Molecular Cancer

Article Title: Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

doi: 10.1186/s12943-024-02167-9

Figure Lengend Snippet: Clinical trials of multitarget TKIs in lung cancer

Article Snippet: These approaches include small-molecule FGFR inhibitors that target the ATP-binding site of the tyrosine kinase domain of various growth factor receptors (multitarget TKIs), selective TKIs that specifically target the kinase domain of FGFRs, and biological agents (Fig. ).

Techniques: Clinical Proteomics, Control, Amplification, Adjuvant

Journal: Molecular Cancer

Article Title: Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

doi: 10.1186/s12943-024-02167-9

Figure Lengend Snippet: Clinical trials of selective FGFR inhibitors in lung cancer

Article Snippet: These approaches include small-molecule FGFR inhibitors that target the ATP-binding site of the tyrosine kinase domain of various growth factor receptors (multitarget TKIs), selective TKIs that specifically target the kinase domain of FGFRs, and biological agents (Fig. ).

Techniques: Clinical Proteomics

Journal: Molecular Cancer

Article Title: Clinical advances and challenges in targeting FGF/FGFR signaling in lung cancer

doi: 10.1186/s12943-024-02167-9

Figure Lengend Snippet: Resistance mechanisms of targeted FGFR therapies in lung cancer. In addition to FGFR mutations, changes in signaling pathways and the tumor microenvironment confer resistance to targeted FGFR therapies in lung cancer. ( A ) Bypass and downstream pathway activation. ( B ) Multidrug resistance pathway activation and DNA damage inhibition. ( C ) Cytokine reprogramming in the tumor microenvironment

Article Snippet: These approaches include small-molecule FGFR inhibitors that target the ATP-binding site of the tyrosine kinase domain of various growth factor receptors (multitarget TKIs), selective TKIs that specifically target the kinase domain of FGFRs, and biological agents (Fig. ).

Techniques: Protein-Protein interactions, Activation Assay, Inhibition